Iodine seeds in the treatment of slowly proliferating tumours in the head and neck region.
Locally recurrent/persistent disease is a major cause of morbidity and mortality in patients suffering from tumours arising in the head and neck region. Iodine-125, with its long half-life of 60 days, is particularly suited for the treatment of slowly proliferating tumours (e.g. adenoidcystic carcinomas) of this site. We report our experience with 18 patients using iodine-125 seeds, placed at the time of surgery in patients with such tumours. Eleven of the patients were treated for recurrent disease following previous radical treatment. Disease free survival was 89% at 2 years and 53% at 5 years after treatment. These results are encouraging in a group of patients in whom achieving and maintaining local control can be extremely difficult.
Glaser
M G
MG
Department of Radiotherapy and Oncology, Charing Cross Hospital, London, UK.
Leslie
M D
MD
Coles
I
I
Cheesman
A D
AD
D000328:Adult; D000368:Aged; D001918:Brachytherapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D007457:Iodine Radioisotopes